Skip to content
Screener

Kura Oncology KURA Q1 2025 earnings

Reported May 1, 2025 · After market close

Revenue$14.1MMiss by $52.6M
EPS-$0.66Miss by $0.15
Revenue estimate$66.7M
EPS estimate-$0.51

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$23.8M
EPS estimate-$0.84

Financials

Q1 2025

Income statement

See full
Revenue$14.1M+4.7%
Operating income-$64.7M-18.8%
Net income-$57.4M-16.0%
EPS (diluted)-$0.66-11.9%

Balance sheet

See full
Cash & equivalents$51.3M+23.5%
Total debt$19.4M+14.0%
Total equity$364.4M-27.9%
Total assets$743.8M+34.3%

Cash flow

See full
Operating cash flow-$71.9M-47.3%
CapEx$292.0K+248%
Free cash flow-$72.2M-47.6%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$532.98M-70.2%
Enterprise value$501.07M-71.6%
P/S9.8×-123×

Profitability

See full
Operating margin-373.2%-156pp
Net margin-333.6%-141pp
FCF margin202.8%+111pp

Returns & leverage

See full
Return on equity-41.8%+5.7pp
Debt / equity0.1×0.0×
Current ratio8.1×-8.6×

Segments

By product

See full
License And Collaboration Revenue$14.1M+4.7%

FAQ

When did Kura Oncology report Q1 2025 earnings?
Kura Oncology (KURA) reported Q1 2025 earnings on May 1, 2025 after market close.
What were Kura Oncology's Q1 2025 revenue and EPS?
Kura Oncology reported revenue of $14.1M and eps of $-0.66 for Q1 2025.
Did Kura Oncology beat estimates in Q1 2025?
Revenue missed the consensus estimate of $66.7M by $52.6M. EPS missed the consensus estimate of $-0.51 by $0.15.
How did Kura Oncology's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 11.9% from $-0.59.
Where can I find Kura Oncology's Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-061836) and the 10-Q periodic report (0000950170-25-061848) directly on SEC EDGAR. The filing index links above go to sec.gov.